Core Viewpoint - Rosen Law Firm is urging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to stock purchases made between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients, including malfunctions that could result in underinfusion, overinfusion, or non-delivery of fluids [6]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Performance - Western Alliance Bancorporation initiated a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation Details - The investigation is prompted by a report indicating that Firefly Aerospace may have provided misleading information regarding its business performance [1]. - Shareholders who purchased Firefly Aerospace securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. Group 2: Financial Performance - On September 22, 2025, The Wall Street Journal reported that Firefly Aerospace posted a wider loss and lower revenue in its latest quarter, marking its first earnings report since its stock market debut [3]. - Following the publication of this report, Firefly's stock experienced a decline of 15.3% on September 23, 2025 [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class actions [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period, highlighting potential misrepresentation regarding the market demand for its sleep apnea device, Inspire V [2][6]. Group 1: Class Action Details - The class action lawsuit pertains to purchases made between August 6, 2024, and August 4, 2025, and aims to address alleged misrepresentations by the company regarding the demand and launch of the Inspire V device [2][6]. - Investors who purchased Inspire Medical common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Legal Process and Participation - Interested investors can join the class action by submitting a form or contacting the law firm directly, with a deadline to serve as lead plaintiff set for January 5, 2026 [4][7]. - It is noted that no class has been certified yet, meaning investors are not represented by counsel unless they retain one [8]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has consistently ranked highly in terms of securities class action settlements and has recovered hundreds of millions of dollars for investors over the years [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of Nidec Corporation shareholders due to allegations of materially misleading business information issued by the company [2][3]. Group 1: Investigation Details - The investigation is prompted by a significant drop in Nidec's stock price, which fell 22% following a report of accounting issues related to its management [4]. - Nidec's American Depositary Receipts (ADRs) experienced a decline of 22.7% on September 4, 2025, marking the largest one-day drop for the company [4]. Group 2: Class Action Information - Investors who purchased Nidec Corporation securities may be eligible for compensation through a class action lawsuit, with no upfront costs due to a contingency fee arrangement [3]. - Interested investors can join the prospective class action by submitting a form or contacting the law firm directly [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [5]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [5].

Core Viewpoint - MoonLake Immunotherapeutics faced a significant decline in share price following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a securities class action lawsuit alleging misleading statements about the drug's efficacy and trial design [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy of SLK being substantially lower than that of the competitor's FDA-approved product, BIMZELX [6]. - Following the announcement on September 28, 2025, MoonLake's share price plummeted by $55.75, approximately 90%, on September 29, 2025 [2][6]. Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors regarding SLK's trial design and efficacy, asserting that the company made false statements about the advantages of SLK's Nanobody structure over traditional monoclonal antibodies [5][6]. - Specific allegations include misleading claims about the clinical benefits of SLK compared to BIMZELX, including the assertion that SLK would achieve superior clinical responses and could become the "gold standard" treatment [5][6]. Legal Proceedings - A securities class action has been filed against MoonLake, with a focus on the company's statements about SLK's trial design and data [1][3]. - The lead plaintiff deadline for the class action is set for December 15, 2025 [3].

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [5]. - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by December 29, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [4] - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [4] - The allegations suggest that these actions subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Nidec Corporation due to allegations of materially misleading business information [1] Group 1: Investigation Details - The investigation is prompted by a significant drop in Nidec's share price following allegations of improper accounting practices within its China unit [3] - On September 4, 2025, Nidec's American Depositary Receipts (ADRs) fell by 22.7%, marking the largest one-day decline for the company [3] Group 2: Class Action Information - Shareholders who purchased Nidec Corporation securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2] - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4] - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by claims that Agilon Health may have misled investors regarding its business performance [1]. - Shareholders who purchased Agilon Health securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. Group 2: Company Performance - On August 4, 2025, Agilon Health announced its second quarter results, indicating that industry headwinds were more severe than previously anticipated [3]. - Following this announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 3: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of achieving substantial settlements for investors, including over $438 million in 2019 alone [4].